Nanlin Li
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer (NCT07115095) | Nanlin Li | 2021-01-01 |
Track Nanlin Li automatically
Every clearance here is in the API, with alerts when new ones post.